Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

• Market Cap: ¥148.24B
• Dividend Yield: 5.18%
• Average Volume (3M): 47.44K
• Price to Earnings (P/E): 18.5
• Beta (1Y): 0.43
• Revenue Growth: 1.51%
• EPS Growth: 5.48%
• Country: JP
• Employees: 1,369
• Sector: Consumer Defensive
• Sector Strength: 55
• Industry: Household & Personal Products
• EPS (TTM): 48.83
• Shares Outstanding: 34,156,624
• 10 Day Avg. Volume: 51,290
• 30 Day Avg. Volume: 47,443
• PEG Ratio: 1.35
• Price to Book (P/B): 3.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 37.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: ¥4,798.00 ▲(10.55%Upside)

Noevir Holdings Co., Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet. The valuation is appealing, driven by a reasonable P/E ratio and a high dividend yield. Technical indicators show mixed signals, with potential short-term weakness but also signs of being oversold, which could offer buying opportunities. The absence of recent earnings call data or notable corporate events results in these components not influencing the score.

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Noevir Holdings Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of cosmetics, pharmaceuticals, and health-food products. The company operates through various segments, including Cosmetics, Pharmaceuticals, and Others. Its core products include skincare, makeup, and nutritional supplements, designed to enhance beauty and wellness. Noevir is known for its high-quality, innovative formulas and its commitment to research and development, leveraging both traditional and modern scientific approaches to create effective and safe products.

How the Company Makes Money

Noevir Holdings Co., Ltd. generates revenue through its diversified product lines across several key segments. The primary revenue stream comes from the Cosmetics segment, which includes the sale of skincare, makeup, and beauty products. This segment benefits from a well-established distribution network, including direct sales channels and retail partnerships. Additionally, Noevir earns income from its Pharmaceuticals segment, which includes the development and sale of health-related products and over-the-counter medications. The company also capitalizes on its Health Food segment, offering nutritional and dietary supplements. Moreover, Noevir's investments in research and development contribute to its competitive edge, ensuring a steady pipeline of new and innovative products. Strategic partnerships and collaborations also play a role in expanding its market reach and enhancing its brand presence globally.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary

Noevir Holdings Co., Ltd. presents a strong financial profile with consistent profitability and a robust balance sheet. Revenue and profit margins are solid, while leverage remains low, indicating financial prudence. However, cash flow generation shows some decline, which, although still sufficient, could affect future investment capacity.

Income Statement

The income statement reveals a positive trajectory with stable revenue growth, evidenced by a 2.3% increase in revenue from the previous year. The gross profit margin remains strong at 67.06% for TTM, and the net profit margin is healthy at 12.48%. EBIT and EBITDA margins indicate efficient operations with EBIT at 17.08% and EBITDA at 19.04%. While the company shows consistent profitability, slight fluctuations in EBIT suggest some operational cost pressures.

Balance Sheet

The balance sheet shows a robust financial position with a low debt-to-equity ratio of 0.02, reflecting minimal leverage. The equity ratio is strong at 66.45%, indicating substantial equity financing. Return on equity stands at 16.59%, demonstrating effective use of equity to generate profits. Overall, the balance sheet highlights financial stability, though the slight decrease in stockholders' equity warrants monitoring.

Cash Flow

Cash flow analysis shows a decrease in operating cash flow year-over-year, with a TTM free cash flow growth rate of -37.36%. The operating cash flow to net income ratio is 0.86, while the free cash flow to net income ratio is 0.63, suggesting adequate conversion of net income into free cash flow. Despite some decline in free cash flow, the company maintains sufficient liquidity to support its operations.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	64.23B	63.82B	62.55B	61.14B	51.27B	51.84B
Gross Profit	43.09B	43.16B	42.56B	42.09B	33.03B	33.08B
EBITDA	12.23B	12.63B	12.24B	11.57B	10.05B	9.76B
Net Income	8.01B	7.97B	7.67B	7.59B	6.38B	5.62B
Balance Sheet
Total Assets	72.70B	76.47B	77.25B	76.78B	80.45B	80.05B
Cash, Cash Equivalents and Short-Term Investments	23.80B	29.22B	28.88B	29.75B	31.10B	29.46B
Total Debt	785.00M	828.00M	914.00M	1.00B	1.11B	1.22B
Total Liabilities	23.84B	22.57B	24.04B	24.40B	28.22B	27.81B
Stockholders Equity	48.32B	53.48B	52.79B	52.05B	51.93B	51.98B
Cash Flow
Free Cash Flow	5.08B	8.11B	6.57B	5.23B	8.63B	5.67B
Operating Cash Flow	6.91B	9.12B	7.62B	5.84B	9.06B	7.31B
Investing Cash Flow	-2.40B	1.52B	-3.54B	-255.00M	-416.00M	-1.61B
Financing Cash Flow	-7.87B	-7.71B	-7.49B	-7.38B	-7.18B	-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4340.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Positive. The current price of 4340 is above the 20-day moving average (MA) of 4286.50, above the 50-day MA of 4253.00, and below the 200-day MA of 4586.19, indicating a neutral trend. The MACD of 19.12 indicates Negative momentum. The RSI at 61.30 is Neutral, neither overbought nor oversold. The STOCH value of 75.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4928	74 Outperform	¥148.24B	18.50		5.18%	1.51%	5.48%
Sector *	68 Neutral	¥197.78B	21.08	8.29%	2.34%	4.99%	3.05%
4927	66 Neutral	$279.63B	37.44	4.49%	3.32%	-0.74%	-25.66%
4922	64 Neutral	$336.37B	57.42	2.08%	2.37%	4.63%	-60.17%
4911	60 Neutral	¥1.05T	496.62		1.52%	-1.33%	-139.30%
4967	60 Neutral	$390.25B	36.51	5.17%	1.67%	-8.36%	-38.35%
4912	59 Neutral	$398.82B	18.74	7.58%	2.04%	2.30%	33.87%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Mixed Financial Results for First Half of Fiscal Year 2025

Noevir Holdings reported its consolidated financial results for the first six months of the fiscal year ending September 30, 2025, showing a slight increase in net sales by 1.3% compared to the previous year. However, the company faced a decline in operating and ordinary income, with operating income dropping by 7.3% and ordinary income by 3.5%. Despite these challenges, net income attributable to owners of the parent increased by 1.7%. The equity ratio also decreased from 69.9% to 66.5%, indicating changes in the company’s financial position. The company maintained its dividend forecast, signaling stability in shareholder returns.